贝达药业：与晟斯生物达成战略合作并签署商业合作协议

Core Viewpoint - Beida Pharmaceutical has entered into a strategic cooperation with Jiangsu Shengsi Biopharmaceutical Co., Ltd. and Hangzhou Shengsi Biopharmaceutical Co., Ltd. to enhance its new drug innovation technology platform and expand its product pipeline [1] Group 1: Strategic Cooperation - The strategic cooperation aims to leverage the strengths of both parties to support mutual development [1] - A framework agreement has been signed to facilitate this collaboration [1] Group 2: Market Expansion - The partnership is focused on broadening the treatment areas and restructuring the blood product market [1] - This initiative is intended to better meet clinical needs and strengthen the company's product matrix [1] Group 3: Commercial Agreement - Beida Pharmaceutical has signed a commercial cooperation agreement with Hangzhou Shengsi Biopharmaceutical, granting exclusive distribution rights for the FRSW117 product in the Greater China region [1]